Download PDF
CC BY-NC-ND 4.0 · World J Nucl Med 2022; 21(04): 261-266
DOI: 10.1055/s-0042-1750012
Original Article

18F-Fluorodeoxy Glucose and 11C-Methionine Accumulation in Demyelinating Lesions

Noriaki Tomura
1   Department of Neuroradiology, Radiology, and Neurology, Southern Tohoku Research Institute for Neuroscience, Southern Tohoku General Hospital, Koriyama City, Fukushima, Japan
,
Toshiyuki Saginoya
1   Department of Neuroradiology, Radiology, and Neurology, Southern Tohoku Research Institute for Neuroscience, Southern Tohoku General Hospital, Koriyama City, Fukushima, Japan
,
Chikako Kaneko
1   Department of Neuroradiology, Radiology, and Neurology, Southern Tohoku Research Institute for Neuroscience, Southern Tohoku General Hospital, Koriyama City, Fukushima, Japan
› Author Affiliations Funding None.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Background Few studies have evaluated the accumulation of 18F-fluorodeoxyglucose (FDG), 11C-methionine (MET), and other positron emission tomography (PET) tracers in patients with demyelinating disease.

Purpose This study aimed to investigate the accumulation of FDG-PET/computed tomography (CT) and MET-PET/CT in demyelinating lesions.

Material and Methods A retrospective search of the patient database in our hospital identified five patients with demyelinating disease in whom PET studies performed in the past 10 years revealed accumulation of FDG or MET. The clinical diagnoses were multiple sclerosis (n=1), myelitis (n=1), limbic encephalitis (n=1), chronic inflammatory demyelinating polyneuropathy (CIDP; n=1), and acute demyelinating encephalomyelitis (ADEM; n=1). Two patients received FDG-PET/CT alone and three patients received both FDG-PET/CT and MET-PET/CT on the same day. Images were visually and conjointly reviewed by two radiologists. In semiquantitative evaluation, the maximum standardized uptake value (SUVmax) of the lesion was measured. The lesion-to-normal brain uptake ratio (L/N ratio) was calculated.

Results FDG and/or MET accumulated to a part of the lesions seen on MRI. SUVmax on FDG-PET/CT ranged from 3.8 to 10.3, and L/N ratio on MET-PET/CT ranged from 16.6 to 2.4.

Conclusion It has been established that neoplastic and demyelinating lesions can be differentiated on the basis of FDG or MET uptake. However, as accumulation of FDG and MET can also occur in demyelinating lesions; knowledge of this possibility is of clinical importance.

Keywords

18F fluorodeoxy glucose - 11C methionine - demyelinating disease


Publication History

Article published online:
02 September 2022

© 2022. World Association of Radiopharmaceutical and Molecular Therapy (WARMTH). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Kostakoglu L, Agress Jr., H, Goldsmith SJ. Clinical role of FDG PET in evaluation of cancer. Radigraphics 2003; 23 (02) 315-340 , quiz 533
    CrossrefPubMedGoogle Scholar
  • 2 Kazama T, Faria SC, Varavithya V, Phongkitkarun S, Ito H, Macapinlac HA. FDG PET in the evaluation of treatment for lymphoma: clinical usefulness and pitfalls. Radiographics 2005; 25 (01) 191-207
    CrossrefPubMedGoogle Scholar
  • 3 Palanichamy K, Chakravarti A. Diagnostic and prognostic significance of methionine uptake and methionine positron emission tomography imaging in gliomas. Front Oncol 2017; 7: 257
    CrossrefPubMedGoogle Scholar
  • 4 Tomura N, Mizuno Y, Saginoya T. PET/CT findings for tumors in the base of the skull: Comparison of 18F-FDG with 11C-methionine. Acta Radiol 2016; 57: 325-332
    CrossrefPubMedGoogle Scholar
  • 5 Terakawa Y, Tsuyuguchi N, Iwai Y. et al. Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med 2008; 49 (05) 694-699
    CrossrefPubMedGoogle Scholar
  • 6 Suh CH, Kim HS, Jung SC, Choi CG, Kim SJ. MRI findings in tumefactive demyelinating lesions: a systematic review and meta-analysis. AJNR Am J Neuroradiol 2018; 39 (09) 1643-1649
    CrossrefPubMedGoogle Scholar
  • 7 Takenaka S, Shinoda J, Asano Y. et al. Metabolic assessment of monofocal acute inflammatory demyelination using MR spectroscopy and (11)C-methionine-, (11)C-choline-, and (18)F-fluorodeoxyglucose-PET. Brain Tumor Pathol 2011; 28 (03) 229-238
    CrossrefPubMedGoogle Scholar
  • 8 Kim JE, Choi KG, Jeong JH, Kang HJ, Kim HS. Diffuse cortical hypometabolism on (18)F-FDG-PET scan in a case of an adult variant cerebello-brainstem dominant form of ALD manifesting dementia. Parkinsonism Relat Disord 2012; 18 (02) 210-212
    CrossrefPubMedGoogle Scholar
  • 9 Dolic K, Bilic I, Buca A, Radovic D, Titlic M. differentiation of tumefactive demyelinating lesions from metastatic brain disease with FDG-PET-CT: A case report. J Mult Scler (Foster City) 2014; 1: 1-3
    CrossrefGoogle Scholar
  • 10 Abdoli M, Freedman MS. Neuro-oncology dilemma: tumour or tumefactive demyelinating lesion. Mult Scler Relat Disord 2015; 4 (06) 555-566
    CrossrefPubMedGoogle Scholar
  • 11 Ninomiya S, Hara M, Morita A. et al. Tumefactive demyelinating lesion differentiated from a brain tumor using a combination of magnetic resonance imaging and 11C-methionine positron emission tomography. Intern Med 2015; 54 (11) 1411-1414
    CrossrefPubMedGoogle Scholar
  • 12 Scheid R, Lincke T, Voltz R, von Cramon DY, Sabri O. Serial 18F-fluoro-2-deoxy-D-glucose positron emission tomography and magnetic resonance imaging of paraneoplastic limbic encephalitis. Arch Neurol 2004; 61 (11) 1785-1789
    CrossrefPubMedGoogle Scholar
  • 13 Flanagan EP, Hunt CH, Lowe V. et al. [(18)F]-fluorodeoxyglucose-positron emission tomography in patients with active myelopathy. Mayo Clin Proc 2013; 88 (11) 1204-1212
    CrossrefPubMedGoogle Scholar
  • 14 Shirai S, Yabe I, Kano T. et al. Usefulness of 11C-methionine-positron emission tomography for the diagnosis of progressive multifocal leukoencephalopathy. J Neurol 2014; 261 (12) 2314-2318
    CrossrefPubMedGoogle Scholar
  • 15 Tomura N, Ito Y, Matsuoka H. et al. PET findings of intramedullary tumors of the spinal cord using [18F] FDG and [11C] methionine. AJNR Am J Neuroradiol 2013; 34: 1278-1283
    CrossrefPubMedGoogle Scholar
  • 16 Rahman WT, Wale DJ, Viglianti BL. et al. The impact of infection and inflammation in oncologic 18F-FDG PET/CT imaging. Biomed Pharmacother 2019; 117: 109168
    CrossrefPubMedGoogle Scholar
  • 17 Rangan K, Ravina M, Yadav N, Suraj AS, Gambhir S. 18F-FDG PET/CT of tuberculosis meningitis and carotid pseudoaneurysm. Clin Nucl Med 2017; 42 (06) e304-e305
    CrossrefPubMedGoogle Scholar
  • 18 Lee BY, Newberg AB, Liebeskind DS, Kung J, Alavi A. FDG-PET findings in patients with suspected encephalitis. Clin Nucl Med 2004; 29 (10) 620-625
    CrossrefPubMedGoogle Scholar
  • 19 Kassubek J, Juengling FD, Nitzsche EU, Lücking CH. Limbic encephalitis investigated by 18FDG-PET and 3D MRI. J Neuroimaging 2001; 11 (01) 55-59
    CrossrefPubMedGoogle Scholar
  • 20 Mertens K, Acou M, Van den Broecke C. et al. Progressive multifocal leukoencephalopathy (PML) mimicking high-grade glioma on delayed F-18 FDG PET imaging. J Clin Neurosci 2012; 19 (08) 1167-1169
    CrossrefPubMedGoogle Scholar
  • 21 Masangkay N, Basu S, Moghbel M, Kwee T, Alavi A. Brain 18F-FDG-PET characteristics in patients with paraneoplastic neurological syndrome and its correlation with clinical and MRI findings. Nucl Med Commun 2014; 35 (10) 1038-1046
    CrossrefPubMedGoogle Scholar
  • 22 Maffione AM, Rampin L, Grassetto G, L'Erario R, Colletti PM, Rubello D. 18F-FDG PET/CT in tumefactive multiple sclerosis. Clin Nucl Med 2014; 39 (08) 750-751
    CrossrefPubMedGoogle Scholar
  • 23 Cózar Santiago MdelP, Sanchez Jurado R, Sanz Llorens R, Aguilar Barrios JE, Ferrer Rebolleda J. Limbic encephalitis diagnosed with 18F-FDG PET/CT. Clin Nucl Med 2016; 41 (02) e101-e103
    CrossrefPubMedGoogle Scholar
  • 24 Dong A, Gao M, Wang Y, Gao L, Zuo C. FDG PET/CT in acute tumefactive multiple sclerosis occurring in a case of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Clin Nucl Med 2016; 41 (09) e414-e416
    CrossrefPubMedGoogle Scholar
  • 25 Moloney P, Boylan R, Elamin M, O'Riordan S, Killeen R, McGuigan C. Semi-quantitative analysis of cerebral FDG-PET reveals striatal hypermetabolism and normal cortical metabolism in a case of VGKCC limbic encephalitis. Neuroradiol J 2017; 30 (02) 160-163
    CrossrefPubMedGoogle Scholar
  • 26 Taneja S, Suri V, Ahuja A, Jena A. Simultaneous 18F-FDG PET/MRI in autoimmune limbic encephalitis. Indian J Nucl Med 2018; 33 (02) 174-176
    CrossrefPubMedGoogle Scholar
  • 27 Ishibashi K, Miura Y, Matsumura K. et al. PET imaging of 18F-FDG, 11C-methionine, 11C-fumazenil and 11C–4DST in progressive multifocal leukoencephalopathy. Intern Med 2017; 56 (10) 1219-1223
    CrossrefPubMedGoogle Scholar
  • 28 Hashimoto S, Inaji M, Nariai T. et al. Usefulness of [11C] methionine PET in the differentiation of tumefactive multiple sclerosis from high grade astrocytoma. Neurol Med Chir (Tokyo) 2019; 59 (05) 176-183
    CrossrefPubMedGoogle Scholar
  • 29 Bolcaen J, Acou M, Mertens K. et al. Structural and metabolic features of two different variants of multiple sclerosis: a PET/MRI study. J Neuroimaging 2013; 23 (03) 431-436
    CrossrefPubMedGoogle Scholar
  • 30 Zhang M, Liu J, Li B, Chen S. 18F-florbetapir PET/MRI for quantitatively monitoring demyelination and remyelination in acute disseminated encephalomyelitis. EJNMMI Res 2019; 9 (01) 96
    CrossrefPubMedGoogle Scholar